BioScrip (BIOS) Lifted to “Buy” at BidaskClub
BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a hold rating to a buy rating in a research report released on Saturday morning.
Other research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of BioScrip from a sell rating to a hold rating in a research report on Wednesday, January 10th. ValuEngine upgraded shares of BioScrip from a strong sell rating to a sell rating in a research report on Thursday, November 9th. Finally, SunTrust Banks restated a buy rating and set a $3.00 price objective on shares of BioScrip in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $3.63.
BioScrip (NASDAQ:BIOS) opened at $2.97 on Friday. BioScrip has a 1 year low of $1.35 and a 1 year high of $3.39. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60.
COPYRIGHT VIOLATION NOTICE: “BioScrip (BIOS) Lifted to “Buy” at BidaskClub” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2018/02/11/bioscrip-bios-lifted-to-buy-at-bidaskclub.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.